Findings

What do systematic reviews say?

116 questions · 120 findings · 14 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 14 · 11.7%GRADE not reported 5 · 4.2%Very low 29 · 24.2%Low 44 · 36.7%Moderate 27 · 22.5%High 1 · 0.8%

Oral creatine vs placebo

Change in quality of life · children with SMA types II and III

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 38 participants
Low

Oral creatine vs placebo

Change in pulmonary function · children with SMA types II and III

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 23 participants
Low

Oral olesoxime vs placebo

Change in disability score · non‐ambulatory children and adolescents with SMA types II and III

4 findings from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 160 participants
Very low
Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 160 participants
Very low
Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
RR 1.43
1 study · 160 participants
Very low

Show 1 more finding

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 160 participants
Low

Oral olesoxime vs placebo

Muscle strength · non‐ambulatory children and adolescents with SMA types II and III

The review found no eligible studies for this question.

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Oral olesoxime vs placebo

Acquiring the ability to stand or walk · non‐ambulatory children and adolescents with SMA types II and III

The review found no eligible studies for this question.

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Oral olesoxime vs placebo

Change in quality of life · non‐ambulatory children and adolescents with SMA types II and III

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 108 participants
Low

Oral olesoxime vs placebo

Change in pulmonary function · non‐ambulatory children and adolescents with SMA types II and III

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 102 participants
Low

Continuous oral valproate vs placebo or no treatment

Recurrent seizure at 6 months · children with febrile seizures

Continuous oral valproate showed no clear difference in recurrent seizure at 6 months compared with placebo or no treatment (low certainty).

1 finding from 1 review

Prophylactic drug management for febrile seizures in children 2021 · Cochrane Headline outcomes only
RR 1.2 [0.55, 2.62]
2 studies · 156 participants
Low

Continuous oral valproate vs placebo or no treatment

Recurrent seizure at 12 months · children with febrile seizures

Continuous oral valproate showed no clear difference in recurrent seizure at 12 months compared with placebo or no treatment (low certainty).

1 finding from 1 review

Prophylactic drug management for febrile seizures in children 2021 · Cochrane Headline outcomes only
RR 0.82 [0.52, 1.29]
4 studies · 255 participants
Low

Continuous oral valproate vs placebo or no treatment

Recurrent seizure at 18 months · children with febrile seizures

It is very uncertain whether continuous oral valproate changes recurrent seizure at 18 months compared with placebo or no treatment (very low certainty).

1 finding from 1 review

Prophylactic drug management for febrile seizures in children 2021 · Cochrane Headline outcomes only
RR 0.13 [0.02, 0.96]
1 study · 48 participants
Very low

Continuous oral valproate vs placebo or no treatment

Recurrent seizure at 24 months · children with febrile seizures

Continuous oral valproate showed no clear difference in recurrent seizure at 24 months compared with placebo or no treatment (low certainty).

1 finding from 1 review

Prophylactic drug management for febrile seizures in children 2021 · Cochrane Headline outcomes only
RR 1.26 [0.73, 2.18]
2 studies · 156 participants
Low

Continuous oral valproate vs placebo or no treatment

Recurrent seizure at 36 months · children with febrile seizures

The review found no eligible studies for this question.

1 finding from 1 review

Prophylactic drug management for febrile seizures in children 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Continuous oral valproate vs placebo or no treatment

Recurrent seizure at 48 months · children with febrile seizures

The review found no eligible studies for this question.

1 finding from 1 review

Prophylactic drug management for febrile seizures in children 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Continuous oral valproate vs placebo or no treatment

Recurrent seizure at 60 months or greater · children with febrile seizures

The review found no eligible studies for this question.

1 finding from 1 review

Prophylactic drug management for febrile seizures in children 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Oral gabapentin vs placebo

Acquiring ability to walk · adults with SMA types II and III

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 73 participants
Low

Oral gabapentin vs placebo

Change in quality of life · adults with SMA types II and III

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 67 participants
Low

Oral gabapentin vs placebo

Change in pulmonary function · adults with SMA types II and III

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 65 participants
Low

Oral gabapentin vs placebo

Change in disability score · adults with SMA types II and III

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 66 participants
Low

Oral gabapentin vs placebo

Muscle strength · adults with SMA types II and III

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 50 participants
Low

Oral hydroxyurea vs placebo

Change in disability score · children and adults with SMA types II and III

2 findings from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 57 participants
Low
Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 38 participants
Moderate